Cargando…

Early administration of remdesivir may reduce mortality in hospitalized COVID-19 patients: A propensity score matched analysis

BACKGROUND: Remdesivir is the only antiviral agent approved for the treatment of hospitalized coronavirus disease 2019 (COVID-19) patients requiring supplemental oxygen. Studies show conflicting results regarding its effect on mortality. METHODS: In this single center observational study, we include...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karolyi, Mario, Kaltenegger, Lukas, Pawelka, Erich, Kuran, Avelino, Platzer, Moritz, Totschnig, David, Koenig, Franz, Hoepler, Wolfgang, Laferl, Hermann, Omid, Sara, Seitz, Tamara, Traugott, Marianna, Arthofer, Sigrun, Erlbeck, Lea, Jaeger, Stefan, Kettenbach, Alina, Assinger, Alice, Wenisch, Christoph, Zoufaly, Alexander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Vienna 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610353/ https://www.ncbi.nlm.nih.gov/pubmed/36301355 http://dx.doi.org/10.1007/s00508-022-02098-9

Ejemplares similares

Tocilizumab vs. baricitinib in hospitalized severe COVID-19 patients: results from a real-world cohort
por: Karolyi, Mario, et al.
Publicado: (2022)

Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19—Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT)
por: Karolyi, M., et al.
Publicado: (2022)

Late onset pulmonary embolism in young male otherwise healthy COVID-19 patients
por: Karolyi, M., et al.
Publicado: (2020)

COVID-19 is not “just another flu”: a real-life comparison of severe COVID-19 and influenza in hospitalized patients in Vienna, Austria
por: Pawelka, Erich, et al.
Publicado: (2021)

Correction to: COVID-19 is not “just another flu”: a real-life comparison of severe COVID-19 and influenza in hospitalized patients in Vienna, Austria
por: Pawelka, Erich, et al.
Publicado: (2021)

High Dose Lopinavir/Ritonavir Does Not Lead to Sufficient Plasma Levels to Inhibit SARS-CoV-2 in Hospitalized Patients With COVID-19
por: Karolyi, Mario, et al.
Publicado: (2021)

541. The Effect of Early Remdesivir Administration in COVID-19 Disease Progression
por: Platzer, Moritz, et al.
Publicado: (2023)

Detection of bacteria via multiplex PCR in respiratory samples of critically ill COVID-19 patients with suspected HAP/VAP in the ICU
por: Karolyi, Mario, et al.
Publicado: (2021)

Clinical and Angiographic Features in Three COVID-19 Patients with Takotsubo Cardiomyopathy. Case Report
por: Hoepler, Wolfgang, et al.
Publicado: (2021)

COVID-19-associated myoclonus in a series of five critically ill patients
por: Grieb, Alexander, et al.
Publicado: (2021)

Comparison of clinical characteristics among patients infected with alpha vs. delta SARS-CoV-2 variants
por: Rumpf, Benedikt, et al.
Publicado: (2022)

Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients: Results from a real-life patient cohort
por: Karolyi, Mario, et al.
Publicado: (2020)

Rapid Detection of Bacterial and Fungal Pathogens Using the T2MR versus Blood Culture in Patients with Severe COVID-19
por: Seitz, Tamara, et al.
Publicado: (2022)

Successful management of the first reported case in Austria of COVID-19 with ARDS
por: Seitz, T., et al.
Publicado: (2020)

Diagnosis of COVID-19 using multiple antibody assays in two cases with negative PCR results from nasopharyngeal swabs
por: Traugott, Marianna Theresia, et al.
Publicado: (2020)

Is there a clinical difference between influenza A and B virus infections in hospitalized patients?: Results after routine polymerase chain reaction point-of-care testing in the emergency room from 2017/2018
por: Karolyi, Mario, et al.
Publicado: (2019)

Evaluation of Five Commercial SARS-CoV-2 Antigen Tests in a Clinical Setting
por: Seitz, Tamara, et al.
Publicado: (2022)

Human recombinant soluble ACE2 in severe COVID-19
por: Zoufaly, Alexander, et al.
Publicado: (2020)

SARS-CoV-2 Pre-Exposure Prophylaxis with Sotrovimab and Tixagevimab/Cilgavimab in Immunocompromised Patients—A Single-Center Experience
por: Totschnig, David, et al.
Publicado: (2022)

Monkeypox associated acute arthritis
por: Fonti, Mirella, et al.
Publicado: (2022)

Diagnostik und Therapie von COVID-19 auf der Intensivstation
por: Hoepler, Wolfgang, et al.
Publicado: (2022)

Efficacy of Sotrovimab (SOT), Molnupiravir (MOL), and Nirmatrelvir/Ritponavir (N/R) and Tolerability of Molnupiravir in Outpatients at High Risk for Severe COVID-19
por: Kauer, Victoria, et al.
Publicado: (2023)

The natural killer cell‐associated rs9916629‐C allele is a novel genetic risk factor for fatal COVID‐19
por: Vietzen, Hannes, et al.
Publicado: (2022)

Age Related Differences in Monocyte Subsets and Cytokine Pattern during Acute COVID-19—A Prospective Observational Longitudinal Study
por: Pirabe, Anita, et al.
Publicado: (2021)

Immunoglobulin G production in COVID-19 - associations with age, outcome, viral persistence, inflammation and pro-thrombotic markers
por: Pirabe, Anita, et al.
Publicado: (2023)

Platelet Phenotype Analysis of COVID-19 Patients Reveals Progressive Changes in the Activation of Integrin αIIbβ3, F13A1, the SARS-CoV-2 Target EIF4A1 and Annexin A5
por: Ercan, Huriye, et al.
Publicado: (2021)

Assessment of S1-, S2-, and NCP-Specific IgM, IgA, and IgG Antibody Kinetics in Acute SARS-CoV-2 Infection by a Microarray and Twelve Other Immunoassays
por: Semmler, Georg, et al.
Publicado: (2021)

A retrospective analysis of clinical features of patients hospitalized with SARS-CoV-2 Omicron variants BA.1 and BA.2
por: Groza, Cristina, et al.
Publicado: (2023)

Platelets and Antiplatelet Medication in COVID-19-Related Thrombotic Complications
por: Schrottmaier, Waltraud C., et al.
Publicado: (2022)

Adverse Outcome in COVID-19 Is Associated With an Aggravating Hypo-Responsive Platelet Phenotype
por: Schrottmaier, Waltraud C., et al.
Publicado: (2021)

Molecular diagnosis of autochthonous human anaplasmosis in Austria – an infectious diseases case report
por: Hoepler, Wolfgang, et al.
Publicado: (2020)

Muscle involvement in SARS‐CoV‐2 infection
por: Pitscheider, Lea, et al.
Publicado: (2020)

Correction: A case of fulminant respiratory diphtheria in a 24-year-old Afghan refugee in Austria in May 2022: a case report
por: Traugott, M. T., et al.
Publicado: (2023)

A case of fulminant respiratory diphtheria in a 24-year-old Afghan refugee in Austria in May 2022: a case report
por: Traugott, M. T., et al.
Publicado: (2022)

The Role of Bacterial and Fungal Superinfection in Critical COVID-19
por: Seitz, Tamara, et al.
Publicado: (2022)

115. Evaluation of the Clinical Impact of the T2MR for the Diagnosis of Bloodstream Infections
por: Seitz, Tamara, et al.
Publicado: (2019)

Low-molecular-weight heparin use in coronavirus disease 2019 is associated with curtailed viral persistence: a retrospective multicentre observational study
por: Pereyra, David, et al.
Publicado: (2021)

Renin-angiotensin system inhibitor discontinuation in COVID-19 did not modify systemic ACE2 in a randomized controlled trial
por: Rathkolb, Vincent, et al.
Publicado: (2023)

A Model Predicting Mortality of Hospitalized Covid-19 Patients Four Days After Admission: Development, Internal and Temporal-External Validation
por: Heber, Stefan, et al.
Publicado: (2022)

Treatment of persistent COVID-19 in two B-cell-depleted patients with the monoclonal antibody Sotrovimab
por: Totschnig, David, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sqo9k2pe3mh4rjtql3p7nil29m